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Abstract  
HIV reservoirs are major barriers to the eradication of this infection despite the widespread use 
of combination antiretroviral therapy. Antiretroviral drugs have restricted entry into the brain due 
to the inherent complexities of this tissue (e.g. uniquely structured blood-brain barrier, presence 
of efficient efflux pumps) which makes the brain an ideal potential anatomic reservoir for HIV 
replication. Cerebrospinal fluid (CSF) and plasma blood concentrations are often used to 
approximate drug concentrations within brain tissue; however, for reasons previously listed, drug 
concentrations in these compartments do not necessarily reflect those in the brain. The objective 
of this study was to evaluate the extent of penetration of select antiretroviral agents into the brain 
tissue of two preclinical models of HIV infection: rhesus macaques (n=6) and humanized mice 
(n=12). Liquid chromatography-tandem mass spectrometry (LC-MS/MS) was used to quantify 
efavirenz (EFV), emtricitabine (FTC), and tenofovir (TFV) in blood plasma, CSF, and brain 
tissue. EFV penetrated best into brain tissue in both animal models, and was up to 3.1-fold 
higher in macaques versus mice (p=0.026). FTC and TFV penetration into brain tissue was 1.3 to 
25-fold higher macaques (p=0.004 and p=0.093, respectively). In infected macaques, the CSF-to-
plasma ratios (CPRs) for TFV and FTC were 1.6 and 4-fold higher than the brain tissue-to-
plasma ratio (TPR). CPRs for the remaining macaque samples were 1.3 to 61-fold lower than the 
TPRs, suggesting that more drug is getting into the brain tissue compared to the CSF. These 
results illustrate that CSF drug concentrations may provide underestimations of the penetration 
of antiretrovirals into brain tissue, and that HIV infection may result in lower brain tissue drug 
concentrations.  
Introduction 
More than 1.2 million people in the United States are currently infected with the human 
immunodeficiency virus (HIV) and almost 1 in 8 (12.8%) are unaware of their infection. 1 HIV 
can progress to acquired immune deficiency syndrome (AIDS) which is characterized by having 
a severely compromised immune system, making those with AIDS more susceptible to life-
threatening complications from opportunistic infections or certain cancers. Though first 
discovered several decades ago, HIV/AIDS remains a major global health concern as there is 
currently no cure or universal vaccination available to combat this deadly disease. Combination 
antiretroviral therapy (cART), the use of a combination of three or more antiretroviral drugs, can 
suppress HIV replication and slow or stop progression to AIDS. Despite this, the virus rebounds 
to its pre-cART level in the plasma of nearly all patients after interrupting treatment, even in 
those with previously undetectable plasma viral loads, 2 indicating that current antiretroviral 
treatment options only control viral replication within the blood and do not allow for complete 
eradication of the infection.  
HIV establishes a viral reservoir rapidly after infection and these reservoirs are capable of re-
establishing viremia soon after discontinuation of antiretroviral therapy.3 Some of the infected 
cells present in HIV reservoirs are in the latent or dormant stage (not actively producing new 
HIV), while other infected cells have been postulated to be actively replicating (although this is 
controversial). Suspected HIV anatomic reservoirs include brain tissue, genital tissue, lymph 
nodes, bone marrow, and gut-associated lymphoid tissue.4 The potential for HIV to persist in 
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these areas of the body could represent a major barrier to HIV cure efforts and must be 
considered in all HIV curative strategies. 
HIV crosses the blood-brain barrier and enters the central nervous system early during infection 
and can cause persistent infection and inflammation.5 Both HIV DNA and RNA have been found 
within the brain and CSF from persons at all stages of HIV disease, including those receiving 
antiretroviral therapy.6-7 Continuous inflammation in the brain resulting from HIV infection may 
lead to neurological complications such as HIV-associated dementia or mild neurocognitive 
disorder. Neurocognitive impairment ranging from subtle to severe remains common among 
people with HIV despite widespread use of cART, according to findings from the large 
CHARTER study in 2010.8 In one study, 87% of individuals diagnosed with HIV-associated 
dementia were found to have genetically distinct HIV variants in their CSF that were not 
detected in the periphery, 9 suggesting that independent viral replication occurs in the central 
nervous system of HIV infected patients with severe neurological disease. Viral mutations 
accumulated during this time can lead to drug resistance which may cause certain antiretroviral 
drugs that effectively suppress plasma viral loads to have limited effects on the mutant viral 
strains residing within the central nervous system.  
Several studies have shed light on the phenomenon of HIV viral escape.10-12 HIV CSF viral 
escape can be defined as the presence of detectable HIV in the CSF of patients with undetectable 
plasma HIV RNA levels. One study reported data on 11 HIV infected patients with neurological 
symptoms and HIV CSF viral escape while receiving combined antiretroviral therapy.12 The 
median CSF HIV RNA level was 880 copies/mL and patients had been receiving stable 
combination antiretroviral therapy for a median of 13 months (range: 10-32 months). Eight of 11 
patients had a plasma HIV RNA level < 50 copies/mL, and 3 had plasma HIV RNA blips with 
their CSF HIV RNA level > 1 log higher than their plasma HIV RNA level. Additionally, 
resistance associated mutations were detected in 7 of 8 CSF HIV RNA genotypic strains.12 Such 
studies note the remarkable discrepancy between plasma and CSF HIV viral loads, showing how 
the virus may be present in the CSF even in the absence of detectable plasma HIV RNA levels.  
Antiretroviral (ARV) drugs differ considerably in their ability to cross the blood-brain barrier,5 
preventing some of these agents from easily accessing the brain tissue. With restricted access to 
the brain, these drugs are limited in their ability to exert their full effect, thus allowing for 
ongoing HIV replication and reservoir development within this compartment. Absent the ability 
to perform brain biopsies on patients receiving antiretroviral therapy, it is difficult to determine 
the relative penetration of these drugs into human brain tissue. Currently, CSF drug 
concentrations are used as surrogate markers for assessing antiretroviral exposure within the 
central nervous system; however, the absolute correlation between the two compartments is 
unknown. Evidence from preclinical and clinical studies suggests that drug concentration in CSF 
seems to be reasonably accurate in predicting drug concentration in the brain.13-15 However, 
CSF drug concentrations are not always accurate surrogates for predicting drug concentrations in 
the brain as this largely depends on the physicochemical properties of the drug, the timing 
of CSF sampling, and the unbound drug concentration within the brain.16  
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As evidenced above, the central nervous system is an essential compartment to consider when 
evaluating HIV treatment, prevention, and curative strategies. The purpose of this study was to 
quantify the commonly used antiretroviral agents efavirenz (EFV), emtricitabine (FTC), and 
tenofovir (TFV) in the brain tissue of two preclinical models of HIV infection: rhesus macaques 
and humanized mice by liquid chromatography-tandem mass spectrometry (LC-MS/MS). Rhesus 
macaques and humanized mice are two well-known preclinical models of HIV infection that 
have allowed for more invasive investigation of HIV infection and also for preclinical testing of 
anti-HIV therapies for more than 20 years.17 These specific drugs were not only chosen for the 
popularity of the fixed-dose, “one pill once daily” regimen, but also chosen because of their 
different physiochemical properties. EFV is a small, lipophilic molecule that has central nervous 
system side effects when used therapeutically. Conversely, FTC and TFV are small, hydrophilic 
molecules that do not cross the blood-brain barrier as easily as EFV. My hypothesis is that there 
is a substantial difference in the extent of drug penetration into the central nervous system and, 
although convenient, measurements of CSF concentrations may not be an accurate estimation of 
antiretroviral drug concentrations within brain tissue. Furthermore, ongoing inflammation 
associated with HIV infection compromises the blood-brain barrier and may lead to increased 
antiretroviral drug concentrations with the central nervous system. 
Methods 
Two commonly used preclinical models of HIV infection were used for this study: rhesus 
macaques and hu-HSC-Rag humanized mice. Male rhesus macaques (Macaca mulatta) between 
3 and 7 years of age were dosed once daily with EFV 200 mg orally, TFV 30mg/kg 
subcutaneously, and FTC 16 mg/kg subcutaneously for 10 days. A total of 6 macaques were 
used, 3 of which were uninfected and 3 of which were infected with simian-human 
immunodeficiency virus (SHIV). SHIV infected macaques were infected intravenously with 104.5 
TCID50 of RT-SHIVmac235, with viral loads measured weekly after inoculation. ARV drug dosing 
ended once 4 weeks of durable HIV infection was established, and a final viral load was 
measured during therapy. One day after the final ARV dose was administered, animals were 
euthanized and underwent necropsy. Blood plasma, CSF, and brain tissue were collected during 
necropsy.  
Two cohorts of female hu-HSC-Rag humanized mice, aged 3-6 months (n=6 each) were used for 
this analysis. Flow cytometry was used to quantify the extent of humanization at baseline and at 
4 weeks post-infection. In the first cohort, HIV infected humanized mice (n=3) and uninfected 
humanized mice (n=3) were dosed with EFV 10 mg/kg once daily for 10 days. In the second 
cohort, HIV infected humanized mice (n=3) and uninfected humanized mice (n=3) were dosed 
once daily with TFV 208 mg/kg and FTC 240 mg/kg for 10 days (Figure 1). All drugs were 
administered by oral gavage, and dosing solutions were prepared by solubilizing formulated 
drug. HIV infected mice were infected intraperitoneally with 200 L 2.1 x 106 IU/mL HIVBal D7. 
Plasma HIV RNA was measured weekly beginning two weeks after inoculation and continuing 
for 4 weeks. As with the macaques, ARV drug dosing ended once 4 weeks of durable HIV 
infection was established, and a final viral load was measured during therapy. One day after the 
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final ARV dose was administered, animals were euthanized and underwent necropsy. Blood 
plasma and brain tissue were collected during necropsy. The antiretroviral drug doses used for 
each animal model were chosen based on commonly used treatment doses that have been 
previously studied in HIV cure strategies.18-21 All samples were snap frozen on dry ice and stored 
at -80°C until analysis. 
 
Figure 1: Schematic Representation of the Study Design 
All six macaques (3 uninfected; 3 infected with SHIV) were dosed daily with EFV, TFV, and FTC for 10 days. Six 
mice (3 uninfected; 3 infected with HIV) were dosed once daily with only EFV for 10 days. The other six mice (3 
uninfected; 3 infected with HIV) mice were dosed once daily with TFV and FTC for 10 days. 
Liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) was utilized to 
quantify drug concentrations within CSF, blood plasma, and brain tissue samples. Brain tissue 
was sliced into 10 µm serial tissue sections for mass spectroscopy imaging analyses not included 
in this study. For this study, a single 10 µm slice was homogenized for 3 cycles of 60 seconds at 
5500rpm in 1 mL of 70:30 acetonitrile-1mM ammonium phosphate with a Precellys 24 tissue 
homogenizer (Bertin Technologies, Montigny-le-Bretonneux, France). Plasma, CSF and tissue 
homogenate samples were extracted by protein precipitation with methanol with stable, 
isotopically labeled 13C5-TFV, 13C15N2-FTC, and d5-EFV added as internal standards. A 
Shimadzu high-performance liquid chromatography system was used for separation, and an AB 
SCIEX API 5000 mass spectrometer (AB SCIEX, Foster City, CA, USA) equipped with a turbo 
spray interface was used as the detector under negative ionization for TFV and EFV and positive 
ionization for FTC. Tissue homogenates were analyzed with a set of 10 calibration standards and 
3 quality control samples. Plasma and CSF were analyzed with a set of 11 calibrations standards 
and 5 quality control samples.  The analytical range for tissue homogenates was 0.01-50ng/mL, 
while plasma and CSF had a calibration range from 1-20000ng/mL. The precision and accuracy 
of the calibration standards and the quality control samples were within the acceptable range of 
15%. 
Standard curves were used to determine drug concentrations in each sample using tissue slice 
area to calculate the concentration of each drug per mL of sample. Macaque brain tissue areas 
were measured experimentally, and mouse brain tissue slice areas were estimated at 80 mm2. 
After calculating the drug concentrations in each sample, CSF-to-plasma ratios (CPRs) and 
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tissue-to-plasma ratios (TPRs) were calculated for each sample. CPR and TPR ratios are 
indicators of drug penetration from plasma into the CSF, and from plasma into brain tissue, 
respectively. TPRs >1 indicate that there is a higher concentration of drug in brain tissue than 
blood plasma, while a ratio <1 indicates that there is a lower concentration of drug in brain tissue 
than blood plasma.  A ratio of one indicates that there is equal concentration in brain tissue and 
blood plasma.  CPRs are interpreted similarly. CPRs were compared to TPRs in macaques to 
determine how well the CSF reflects brain tissue antiretroviral concentrations. TPRs were used 
to compare drug penetration into brain tissue across macaque and mice species. Wilcoxon rank 
sum tests were used to compare TPR values for infected vs uninfected animal cohorts, pooled 
mouse and pooled NHP values were used for interspecies comparisons. P values less than 0.05 
were considered statistically significant.  
Results  
Table 1 shows the median ARV drug concentrations and ranges for macaques (NHP) and 
humanized mice. Figures 2, 3, and 4 show the interspecies drug comparison for FTC, TFV, and 
EFV respectively.  
Table 1: Median Drug Concentrations in Macaques and Humanized Mice 




















































































FTC 81.2  
(28.7-109) 











EFV 17.5  
(12.6-724) 






FTC 21.9  
(19.2-127) 





TFV 59.1  -- 2.21  -- 0.04 
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(10-62.8) (0.80-2.28) (0.035-0.08) 
EFV 3.57  
(2.74-4.23) 




*Ranges in parentheses 
*Sufficient mouse CSF volume could not be collected  
 
TPR values for FTC in macaques ranged from 0.05-0.80. Brain tissue penetration of FTC was 4-
fold higher in uninfected versus infected macaques (p=0.40) despite similar penetration of drug 
into the CSF, although this did not reach statistical significance. Conversely, mouse data showed 
FTC tissue penetration approximately 2-fold higher in infected animals (p=0.40), but this also 
did not reach statistical significance. Overall, mouse TPR values were up to 9.7-fold lower than 




Figure 2: FTC Interspecies Comparison 
 
The Y axis represents median FTC TPR values. Each species is identified on the X axis, with blue bars representing 
infected animals and orange bars representing uninfected animals. Error bars represent FTC TPR range values. 
Macaque TPR was 1.3 to 9.7-fold higher than mice TPR for FTC brain penetration. Infected macaque FTC TPR was 
1.3-fold higher than infected mice. Uninfected macaque FTC TPR was 9.7-fold higher than uninfected mice TPR.  
 
TPR values for TFV in macaques ranged from 0.01-0.60. Brain tissue penetration of TFV was 3-
fold higher in uninfected versus infected macaques (although not statistically significant; 
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20-fold higher in uninfected animals (p=0.10), but this was also not statistically significant. 
Overall, mouse TPR values were nearly 4-fold lower than corresponding macaque values, but 
not statistically significant (Figure 3; p=0.093). 
 
Figure 3: TFV Interspecies Comparison 
The Y axis represents median TFV TPR values. Each species is identified on the X axis, with blue bars representing 
infected animals and orange bars representing uninfected animals. Error bars represent TFV TPR range values. 
Macaque TPR was 3.8 to 25-fold higher than mice TPR for TFV penetration. Infected macaque TFV TPR was 25-
fold higher than infected mice and uninfected FTC TPR was 3.8-fold higher than uninfected mice TPR.  
 
TPR values for EFV in macaques ranged from 0.26-1.66. Brain tissue penetration of EFV was 
4.5-fold higher in uninfected versus infected macaques (not statistically significant; p=0.10), 
again despite similar penetration of drug into the CSF. Mouse data also showed higher EFV 
tissue penetration in uninfected animals (approximately 6-fold higher; p=0.10). Overall, mouse 
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Figure 4: EFV Interspecies Comparison 
The Y axis represents median EFV TPR values. Each species is identified on the X axis, with blue bars representing 
infected animals and orange bars representing uninfected animals. Error bars represent EFV TPR range values. 
Macaques TPR was 2.5 to 3.1-fold higher than mice TPR for EFV penetration. Infected macaque EFV TPR was 3.1-
fold higher than infected mice and uninfected EFV TPR was 2.5-fold higher than uninfected mice TPR.  
 
Discussion 
Despite advances in antiretroviral therapy, HIV persists during treatment. The brain is a potential 
HIV reservoir that may be a major barrier in the eradication of HIV as antiretroviral drugs have 
restricted access to this area. In addition to being an obstacle for eradication, continuous HIV 
replication in the brain can result in incurable neurological complications. Due to the 
impracticality of obtaining brain samples from patients receiving antiretroviral therapy, it is 
difficult to determine the relative penetration of these drugs into human brain tissue and CSF 
drug concentrations are often used as surrogate markers. The results from this study give better 
insight into how well commonly used antiretroviral agents penetrate into brain tissue and how 
well the CSF drug concentrations serve as surrogate markers.  
ARV plasma concentrations were several orders of magnitude lower than reported steady-state 
plasma trough concentrations in humans, 22-23 despite therapeutic doses being used. EFV plasma 
concentrations were 14 to 495-fold lower and FTC plasma concentrations were 1 to 9-fold lower. 
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were 1 to 6-fold higher than human plasma concentrations. For this reason, TPRs and CPRs are 
utilized in an attempt to normalize any discrepancies in plasma exposure between species. 
ARV TPRs for uninfected macaques were 1.3 to 61-fold higher than their corresponding CPRs, 
suggesting that more drug is penetrating brain tissue than CSF. EFV’s TPR in infected macaques 
was also greater than the CPR. In infected macaques, TFV and FTC had TPR’s 1.6 and 4.1-fold 
lower than their corresponding CPR’s, indicating that more drug is present in CSF than brain 
tissue, and again demonstrating how CSF concentrations may not provide accurate estimations of 
ARV drug concentrations in brain tissue. These results are consistent with previous studies 
demonstrating that brain tissue concentrations of nevirapine, another antiretroviral drug, and 
EFV differ from those in the CSF.24-25 Overall, it appears that the extent of brain tissue 
penetration is differential for each drug and that the CSF may not be an accurate predictor of 
tissue concentrations for ARVs.  
EFV had the highest TPR, hence best brain tissue penetration, amongst all drugs as expected 
given that EFV is more lipophilic than FTC and TFV. The higher TPRs in uninfected macaques 
indicate that the presence of infection may reduce the level of drug penetration into brain tissue. 
One possible explanation for this finding is the overexpression of efflux pumps and upregulation 
of proteins within the blood-brain barrier in an attempt to counteract the inflammation associated 
with HIV infection. In mice, a similar pattern was shown with uninfected mice having a higher 
TPR than infected mice by 5.7 and 20-fold for EFV and TFV, respectively. FTC was 
exceptional, with a TPR 1.8-fold higher in infected mice than uninfected mice indicating that 
more FTC is present in brain tissue of infected mice. Overall, macaques had increased levels of 
ARV penetration into brain tissue when compared to humanized mice which is important to note 
for future pharmacokinetic extrapolation studies across species.  
One limitation of this study is the relatively small sample size. With such a small sample size, we 
did not have enough statistical power to see differences between drug penetration in infected vs 
uninfected animals. Another limitation of this study is that CSF samples were not obtained for 
the mice due to the inability to collect sufficient CSF volume. For this reason, tissue penetration 
ratios could not be compared to the CSF penetration ratios in mice. It would be interesting to see 
if a similar trend of higher TPRs than CPRs was also found in uninfected mice, despite similar 
CSF penetration. In a recent study, EFV was found to have higher tissue penetration in vitro and 
in vivo when compared with CSF and plasma concentrations.25 The animal models used in this 
study are a part of a larger cohort project analyzing antiretroviral drug penetration into several 
other potential HIV reservoirs. Future directions of this research project include evaluating the 
extent of more antiretroviral drugs in brain tissue and other probable HIV reservoirs, 
characterizing drug distribution in reservoirs using mass spectrometry imaging, and performing 
pharmacokinetic modeling across macaques, humanized mice, and humans. The ultimate 
research goal is to allow for better predictions of antiretroviral drug penetration into potential 
anatomic HIV reservoirs in HIV infected patients. 
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